EBE statement on French substitution policy

The French Social Security Bill permits, under certain conditions, a restricted form of substitution of biosimilar products by pharmacists. This differs, however, from the substitution policies for generic products. The EBE statement clarifies the background and sets out the industry stance on this issue.
Download | pdf 68.52 kB